SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

This article is based on a poster originally authored by Ariane Jonetz-Mentzel et al. In biopharmaceutical laboratories, there is an increasing demand for label-free, high-throughput screening based ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...

Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...

The global High Throughput Screening Market was valued at USD 13370 Million in the year 2024 and is projected to reach a revised size of USD 17880 Million by 2031, growing at a CAGR of 4.3% during the ...

Conventional high throughput screening for clinical candidates cannot evaluate over 99% of commercially available molecules, thereby restricting the accessible chemical search space for therapeutic ...

Revvity offers comprehensive solutions designed to help accelerate laboratory workflows, assisting researchers meet targets faster and bring new therapies to market sooner. Our integrated approach ...

Metrion Biosciences, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics. Validated drug discovery assay ...

Anna-Maria earned her PhD in synthetic biology from Eindhoven University of Technology, where she honed her ability to transform complex science into real-world solutions. At Nanoworx, she oversees ...

Optimized chemistry enables direct synthesis of up to 500 bp double stranded fragments “Using our chemical synthesis platform we are able to directly synthesize Twist Multiplexed Gene Fragments as ...